Azilsartan medoxomil plus chlorthalidone fixed-dose combinations in essential hypertension after inadequate response to azilsartan monotherapy

Phase 3, randomised, double-blind trial of azilsartan medoxomil and chlorthalidone in essential hypertension (3 arms), sponsored by Takeda. Primary endpoint: Change from baseline to Week 8 in trough, sitting, clinic systolic blood pressure. Started Jun 2011; status: completed.